Fluvaxin (Suspension) Instructions for Use

ATC Code

J07BB01 (Influenza virus inactivated whole)

Active Substance

Influenza vaccine (split virion), inactivated

Influenza vaccine (split virion), inactivated (BP British Pharmacopoeia)

Clinical-Pharmacological Group

Influenza vaccine for prophylaxis

Pharmacotherapeutic Group

MIBP-vaccine

Pharmacological Action

Inactivated purified split influenza vaccine. Prevents diseases caused by influenza virus type A and B.

It induces the formation of humoral antibodies to hemagglutinins that neutralize influenza viruses. A seroprotective level of antibodies is usually achieved within 7-10 days after vaccine administration. The duration of post-vaccination immunity to homologous or related strains varies from 6 to 12 months.

Indications

Influenza prophylaxis.

ICD codes

Dosage Regimen

Suspension

For different age categories, appropriate vaccine preparations should be used, taking into account contraindications.

Vaccination should be carried out before the start of the influenza epidemic season or taking into account the epidemic situation.

The vaccine is administered intramuscularly or deep subcutaneously. Patients with thrombocytopenia and other disorders of the coagulation system should be given the vaccine subcutaneously. The vaccine must never be administered intravenously under any circumstances.

Adverse Reactions

Systemic reactions possible – slight short-term increase in body temperature, febrile conditions, general malaise (these phenomena disappear on their own within 1-2 days); extremely rarely – neuralgia, paresthesia, convulsions, transient thrombocytopenia, neurological disorders, vasculitis.

Allergic reactions in patients with known sensitivity to individual components of the vaccine – skin itching, urticaria, rash; extremely rarely – severe allergic reactions, such as anaphylactic shock.

Local reactions pain, redness and swelling at the injection site.

Contraindications

Acute infectious diseases, exacerbations of chronic diseases, hypersensitivity to the active or auxiliary components of the vaccine; hypersensitivity to gentamicin sulfate, formaldehyde, merthiolate, sodium deoxycholate, chicken egg protein used in the manufacturing process.

Use in Pregnancy and Lactation

There is currently insufficient data on the embryotoxicity and teratogenicity of this vaccine.

The need to use the vaccine during lactation is decided by the doctor individually.

Special Precautions

This vaccine prevents diseases caused by the influenza virus and does not prevent the development of upper respiratory tract infections caused by other pathogens.

For non-severe acute respiratory viral infections, acute intestinal diseases, vaccination is carried out immediately after the temperature normalizes.

When using the vaccine, it is always necessary to have available means that may be required in case of rare anaphylactic reactions after administration. For this reason, the vaccinated person should be under medical supervision for 30 minutes after immunization.

Following influenza vaccination, false-positive results of serological tests using the ELISA method for the determination of antibodies against HIV 1, hepatitis C, and especially human T-lymphotropic virus 1 (HTLV 1) have been observed, which may be a consequence of the immune response (formation of IgM) to vaccination.

Drug Interactions

The effectiveness of immunization may be reduced due to immunosuppressive therapy carried out simultaneously with it, as well as in the presence of immunodeficiency.

Storage Conditions

Store at 2°C (36°F) to 8°C (46°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.